Andrew J. Hull
J.D., summa cum laude, Regent University School of Law
B.A., summa cum laude, Government, Patrick Henry College
District of Columbia
U.S. District Court for the District of Columbia
U.S. Court of Appeals for the District of Columbia Circuit
Printer Friendly Page
Andrew J. Hull represents clients on matters related to administrative, civil, and criminal investigations and proceedings conducted by the DOJ, DEA, FDA, and state authorities under the federal Controlled Substances Act (CSA), the Federal Food, Drug, and Cosmetic Act, and related state laws and regulations. He also advises clients on compliance with federal and state laws and regulations related to the manufacturing, distributing, and dispensing of controlled substances and prescription drugs, particularly under the federal CSA and the Drug Supply Chain Security Act.
Prior to joining the firm, Mr. Hull served as the law clerk to the DEA’s Chief Administrative Law Judge (ALJ), John J. Mulrooney, II, a position he was awarded through the DOJ’s Attorney General’s Honors Program. As a law clerk, he co-authored with Judge Mulrooney the first in-depth primer for practitioners and pharmacies involved in administrative proceedings and hearings before the DEA, titled Drug Diversion Administrative Revocation and Application Hearings for Medical and Pharmacy Practitioners: A Primer for Navigating Murky, Drug-Infested Waters.
At law school, Mr. Hull served as the editor-in-chief of his school’s law review, and he is the author of numerous publications.
• Represent clients in civil matters, including motions for temporary restraining orders and preliminary injunctions.
• Assist clients in responding to criminal subpoenas and internal investigations; manage related large-volume document productions.
Controlled Substances and Prescription Drugs
• Counsel clients regarding licensing, security, recordkeeping, reporting, and related requirements for manufacturers, distributors, and pharmacies.
• Interact with state regulators, such as pharmacy boards and controlled substance authorities, regarding client-specific issues.
Articles / Publications
see more articles
• A Practical Roadmap for Transitioning State Licenses for Sales of Prescription Drugs and Devices in Corporate Transactions,
• Ninth Circuit Confounds Practice of Medicine and Off-Label Use Issues,
November 1, 2016
• A Matter of Substantial Discretion: A Recent Rift between DEA and Its ALJs Could Significantly Impact Registrants,
• Quality Egg and Jail Time for a Park Doctrine Prosecution,
May 6, 2015
• A Warning Letter on FDA's Expansive Interpretation of Its Facilities - Inspection Authority,
March 13, 2015
see more blog entries
• DEA Administrative Decisions Update: Sex, Drugs, and . . . Rocky Agency Precedent,
April 11, 2017
• DEA Administrative Decisions Update: (Un)official Notice Revisited,
February 22, 2017
• DEA Administrative Hearings Update: Rethinking DEA’s Summary Disposition Power in “Loss of State Authority” Cases,
February 15, 2017
• First Circuit Rejects Fraud-on-FDA Allegations Under False Claims Act,
January 16, 2017
• DEA Administrative Hearings: “Open to the Public” Requires Notice to the Public,
October 26, 2016j